Subscribe
Sign in
Home
Podcast
Notes
Archive
Leaderboard
About
Latest
Top
10x Genomics Continues Clinical Push With Swiss Cancer Collab: Newsletter July 28, 2026
FDA Approves Freenome SimpleScreen test, papers on the “4D Nucleome,” Illumina Pays $30M more for SomaLogic, and more.
15 hrs ago
•
Andrew P. Han
NeoGenomics Q2 Revenues Rise 11 Percent, Company Raises Full-Year Guidance
The Florida-based oncology diagnostics firm posted NGS revenue growth of 26 percent and clinical test volume growth of 2 percent.
16 hrs ago
•
Andrew P. Han
10x Genomics Partners With Swiss Hospital to Find Biomarkers Predicting Cancer Treatment Response
The multi-year study aims to find biomarkers that predict treatment response in multiple tumor types, including breast, bladder, and skin cancers.
18 hrs ago
•
Andrew P. Han
Standard BioTools Gets $30M Illumina Buyout Ahead of Treeline Merger
Standard Bio has also agreed to sell its mass cytometry business, including the CyTOF and Hyperion product lines, to newcomer Multiplex Bio.
Jul 28
•
Andrew P. Han
Lucid Genomics, Genetic Alliance Partner on Access to Rare Disease Analysis Software
The deal highlights how genome interpretation remains a significant expense for many diagnostic labs, even as sequencing costs have fallen.
Jul 28
•
Andrew P. Han
FDA Approves Freenome's SimpleScreen CRC Blood Test
FDA approval triggers a $100 million payment from Abbott under the companies’ commercialization agreement.
Jul 27
•
Andrew P. Han
UC Riverside Lab Lands $2.1M NIH Grant to Decode Stress-Response Circuits
The five-year award from NIGMS will fund research on how cells regulate genes under stress.
Jul 24
•
Andrew P. Han
Cell by Cell: How to Capture a Billion Interactions, with Dino Dicarlo
Cell interaction researcher Dino Di Carlo joins to talk about Japanese ice cream and his proposal to analyze a billion cells to capture their…
Jul 24
•
Andrew P. Han
46:37
AI-First Biotechs Turn to Illumina for Data: Newsletter, July 21, 2026
Freenome goes public, Tempus acquires Personalis, Broad/JAX team up on genome editing, Doudna lab embraces AI, and more.
Jul 21
•
Andrew P. Han
1
New Broad-Led Center Aims to Make Gene Therapies Repeatable
With up to $34.5 million from ARPA-H, the new nonprofit aims to standardize gene-editing therapies for rare diseases, starting with childhood…
Jul 21
•
Andrew P. Han
Happy Hour with Molly Zeller and Andrew P. Han
Tune in to hear our thoughts on Wisconsin beer, mongoose saliva, Roche Axelios, and more.
Jul 20
•
Andrew P. Han
35:34
Burning Rock, Myriad Genetics Expand HRD Testing Partnership
The expanded deal gives Burning Rock a prostate cancer algorithm to add to tests in China and licenses Myriad tech for a new HRD kit to sell elsewhere.
Jul 20
•
Andrew P. Han
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
